- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 239/94 - Atomes d'azote
Détention brevets de la classe C07D 239/94
Brevets de cette classe: 690
Historique des publications depuis 10 ans
|
46
|
41
|
46
|
53
|
30
|
66
|
51
|
39
|
28
|
13
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Araxes Pharma LLC | 90 |
18 |
| The Regents of the University of California | 20720 |
15 |
| NATCO Pharma Limited | 204 |
12 |
| Boehringer Ingelheim International GmbH | 4493 |
10 |
| Gilead Sciences, Inc. | 2220 |
9 |
| Bristol-myers Squibb Company | 4729 |
8 |
| Genentech, Inc. | 4099 |
8 |
| Janssen Pharmaceutica N.V. | 3171 |
7 |
| CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 226 |
7 |
| Dana-Farber Cancer Institute, Inc. | 2662 |
7 |
| Merck Patent GmbH | 5725 |
6 |
| The Trustees of Columbia University in the City of New York | 3643 |
6 |
| Northwestern University | 3540 |
6 |
| Asana Biosciences, LLC | 42 |
6 |
| Chiesi Farmaceutici S.p.A. | 959 |
6 |
| Council of Scientific & Industrial Research | 1445 |
6 |
| Institute of Organic Chemistry and Biochemistry of the AS CR, v.v.i. | 13 |
6 |
| The Scripps Research Institute | 1343 |
6 |
| Teva Pharmaceuticals USA, Inc. | 639 |
6 |
| Beijing Scitech-mq Pharmaceuticals Limited | 41 |
6 |
| Autres propriétaires | 529 |